Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different
We compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 v...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacology and therapeutics 2012-08, Vol.92 (2), p.262-264 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 264 |
---|---|
container_issue | 2 |
container_start_page | 262 |
container_title | Clinical pharmacology and therapeutics |
container_volume | 92 |
creator | Orfali, M Feldman, L Bhattacharjee, V Harkins, P Kadam, S Lo, C Ravi, M Shringarpure, D T Mardekian, J Cassino, C Coté, T |
description | We compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 vs. 3.5, P < 0.05) and fewer total participants (390 vs. 2,566, P < 0.001), but proportions with randomization, blinding, and placebo‐controlled clinical end points were similar, as were development times. We conclude that small studies of appropriate design can support US FDA approval of new medicines for rare diseases.
Clinical Pharmacology & Therapeutics (2012); 92 2, 262–264. doi:10.1038/clpt.2012.87 |
doi_str_mv | 10.1038/clpt.2012.87 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1027834249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1027834249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4077-b62aec1f11d8475f72bad85cfc357abbca87f66bc144e39e48cb6be4ead9f5a83</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCjTPyBYkDWfwRxw63KgtdxLZdVQscLccZL4YkDvZuS_89CbuUG6fRjJ53ZvQg9IKSOSVcvbXtsJszQtlcyUdoRgVnWSG4eIxmhJAyKxkvTtBpSt_HNi-VeopOGJO8pFzOkLsxPvl-i6_j8M306R1ehjtctb731rR4AbfQhqGDfofXMWyj6RIODi_ifpuwCxHfmAjY9A2uQteFHi98ApMg4fNxvvDOQRzDz9ATZ9oEz4_1DH3-8H5TLbPV9cXH6nyV2ZxImdUFM2Cpo7RRuRROsto0SlhnuZCmrq1R0hVFbWmeAy8hV7YuasjBNKUTRvEz9Pqwd4jh5x7STnc-WWhb00PYJ00Jk4rnLC9H9M0BtTGkFMHpIfrOxPsR0pNZPZnVk1mt5Ii_PG7e1x00D_BflSPw6giYNKpz0fTWp39cwYiSZHpRHrg738L9f4_qar2pVuvN1P55ITskfdrBr4ekiT90IbkU-uvVhf6yWV59EpeXesl_A6LqotU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1027834249</pqid></control><display><type>article</type><title>Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Orfali, M ; Feldman, L ; Bhattacharjee, V ; Harkins, P ; Kadam, S ; Lo, C ; Ravi, M ; Shringarpure, D T ; Mardekian, J ; Cassino, C ; Coté, T</creator><creatorcontrib>Orfali, M ; Feldman, L ; Bhattacharjee, V ; Harkins, P ; Kadam, S ; Lo, C ; Ravi, M ; Shringarpure, D T ; Mardekian, J ; Cassino, C ; Coté, T</creatorcontrib><description>We compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 vs. 3.5, P < 0.05) and fewer total participants (390 vs. 2,566, P < 0.001), but proportions with randomization, blinding, and placebo‐controlled clinical end points were similar, as were development times. We conclude that small studies of appropriate design can support US FDA approval of new medicines for rare diseases.
Clinical Pharmacology & Therapeutics (2012); 92 2, 262–264. doi:10.1038/clpt.2012.87</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2012.87</identifier><identifier>PMID: 22739137</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; Drug Approval - legislation & jurisprudence ; Drug Approval - methods ; Drug Discovery - economics ; Drug Discovery - legislation & jurisprudence ; Drug Discovery - methods ; Humans ; Medical sciences ; Orphan Drug Production - economics ; Orphan Drug Production - legislation & jurisprudence ; Orphan Drug Production - methods ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Rare Diseases - drug therapy ; Research Design - legislation & jurisprudence ; Research Design - standards ; Sample Size ; United States ; United States Food and Drug Administration</subject><ispartof>Clinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.262-264</ispartof><rights>2012 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4077-b62aec1f11d8475f72bad85cfc357abbca87f66bc144e39e48cb6be4ead9f5a83</citedby><cites>FETCH-LOGICAL-c4077-b62aec1f11d8475f72bad85cfc357abbca87f66bc144e39e48cb6be4ead9f5a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2012.87$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2012.87$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26208708$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22739137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orfali, M</creatorcontrib><creatorcontrib>Feldman, L</creatorcontrib><creatorcontrib>Bhattacharjee, V</creatorcontrib><creatorcontrib>Harkins, P</creatorcontrib><creatorcontrib>Kadam, S</creatorcontrib><creatorcontrib>Lo, C</creatorcontrib><creatorcontrib>Ravi, M</creatorcontrib><creatorcontrib>Shringarpure, D T</creatorcontrib><creatorcontrib>Mardekian, J</creatorcontrib><creatorcontrib>Cassino, C</creatorcontrib><creatorcontrib>Coté, T</creatorcontrib><title>Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clinical Pharmacology & Therapeutics</addtitle><description>We compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 vs. 3.5, P < 0.05) and fewer total participants (390 vs. 2,566, P < 0.001), but proportions with randomization, blinding, and placebo‐controlled clinical end points were similar, as were development times. We conclude that small studies of appropriate design can support US FDA approval of new medicines for rare diseases.
Clinical Pharmacology & Therapeutics (2012); 92 2, 262–264. doi:10.1038/clpt.2012.87</description><subject>Biological and medical sciences</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Drug Approval - methods</subject><subject>Drug Discovery - economics</subject><subject>Drug Discovery - legislation & jurisprudence</subject><subject>Drug Discovery - methods</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Orphan Drug Production - economics</subject><subject>Orphan Drug Production - legislation & jurisprudence</subject><subject>Orphan Drug Production - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rare Diseases - drug therapy</subject><subject>Research Design - legislation & jurisprudence</subject><subject>Research Design - standards</subject><subject>Sample Size</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EotvCjTPyBYkDWfwRxw63KgtdxLZdVQscLccZL4YkDvZuS_89CbuUG6fRjJ53ZvQg9IKSOSVcvbXtsJszQtlcyUdoRgVnWSG4eIxmhJAyKxkvTtBpSt_HNi-VeopOGJO8pFzOkLsxPvl-i6_j8M306R1ehjtctb731rR4AbfQhqGDfofXMWyj6RIODi_ifpuwCxHfmAjY9A2uQteFHi98ApMg4fNxvvDOQRzDz9ATZ9oEz4_1DH3-8H5TLbPV9cXH6nyV2ZxImdUFM2Cpo7RRuRROsto0SlhnuZCmrq1R0hVFbWmeAy8hV7YuasjBNKUTRvEz9Pqwd4jh5x7STnc-WWhb00PYJ00Jk4rnLC9H9M0BtTGkFMHpIfrOxPsR0pNZPZnVk1mt5Ii_PG7e1x00D_BflSPw6giYNKpz0fTWp39cwYiSZHpRHrg738L9f4_qar2pVuvN1P55ITskfdrBr4ekiT90IbkU-uvVhf6yWV59EpeXesl_A6LqotU</recordid><startdate>201208</startdate><enddate>201208</enddate><creator>Orfali, M</creator><creator>Feldman, L</creator><creator>Bhattacharjee, V</creator><creator>Harkins, P</creator><creator>Kadam, S</creator><creator>Lo, C</creator><creator>Ravi, M</creator><creator>Shringarpure, D T</creator><creator>Mardekian, J</creator><creator>Cassino, C</creator><creator>Coté, T</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201208</creationdate><title>Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different</title><author>Orfali, M ; Feldman, L ; Bhattacharjee, V ; Harkins, P ; Kadam, S ; Lo, C ; Ravi, M ; Shringarpure, D T ; Mardekian, J ; Cassino, C ; Coté, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4077-b62aec1f11d8475f72bad85cfc357abbca87f66bc144e39e48cb6be4ead9f5a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biological and medical sciences</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Drug Approval - methods</topic><topic>Drug Discovery - economics</topic><topic>Drug Discovery - legislation & jurisprudence</topic><topic>Drug Discovery - methods</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Orphan Drug Production - economics</topic><topic>Orphan Drug Production - legislation & jurisprudence</topic><topic>Orphan Drug Production - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rare Diseases - drug therapy</topic><topic>Research Design - legislation & jurisprudence</topic><topic>Research Design - standards</topic><topic>Sample Size</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orfali, M</creatorcontrib><creatorcontrib>Feldman, L</creatorcontrib><creatorcontrib>Bhattacharjee, V</creatorcontrib><creatorcontrib>Harkins, P</creatorcontrib><creatorcontrib>Kadam, S</creatorcontrib><creatorcontrib>Lo, C</creatorcontrib><creatorcontrib>Ravi, M</creatorcontrib><creatorcontrib>Shringarpure, D T</creatorcontrib><creatorcontrib>Mardekian, J</creatorcontrib><creatorcontrib>Cassino, C</creatorcontrib><creatorcontrib>Coté, T</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orfali, M</au><au>Feldman, L</au><au>Bhattacharjee, V</au><au>Harkins, P</au><au>Kadam, S</au><au>Lo, C</au><au>Ravi, M</au><au>Shringarpure, D T</au><au>Mardekian, J</au><au>Cassino, C</au><au>Coté, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clinical Pharmacology & Therapeutics</addtitle><date>2012-08</date><risdate>2012</risdate><volume>92</volume><issue>2</issue><spage>262</spage><epage>264</epage><pages>262-264</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>We compared clinical trials described in package inserts from noncancer orphan and nonorphan drugs from 1 January 2001 to 31 December 2011. Among the 37 orphan and 58 nonorphan drugs approved by the US Food and Drug Administration (US FDA) during this period, orphans had fewer clinical trials (2.8 vs. 3.5, P < 0.05) and fewer total participants (390 vs. 2,566, P < 0.001), but proportions with randomization, blinding, and placebo‐controlled clinical end points were similar, as were development times. We conclude that small studies of appropriate design can support US FDA approval of new medicines for rare diseases.
Clinical Pharmacology & Therapeutics (2012); 92 2, 262–264. doi:10.1038/clpt.2012.87</abstract><cop>Basingstoke</cop><pub>Blackwell Publishing Ltd</pub><pmid>22739137</pmid><doi>10.1038/clpt.2012.87</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9236 |
ispartof | Clinical pharmacology and therapeutics, 2012-08, Vol.92 (2), p.262-264 |
issn | 0009-9236 1532-6535 |
language | eng |
recordid | cdi_proquest_miscellaneous_1027834249 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Biological and medical sciences Drug Approval - legislation & jurisprudence Drug Approval - methods Drug Discovery - economics Drug Discovery - legislation & jurisprudence Drug Discovery - methods Humans Medical sciences Orphan Drug Production - economics Orphan Drug Production - legislation & jurisprudence Orphan Drug Production - methods Pharmacology. Drug treatments Randomized Controlled Trials as Topic Rare Diseases - drug therapy Research Design - legislation & jurisprudence Research Design - standards Sample Size United States United States Food and Drug Administration |
title | Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Raising%20Orphans:%20How%20Clinical%20Development%20Programs%20of%20Drugs%20for%20Rare%20and%20Common%20Diseases%20Are%20Different&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Orfali,%20M&rft.date=2012-08&rft.volume=92&rft.issue=2&rft.spage=262&rft.epage=264&rft.pages=262-264&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2012.87&rft_dat=%3Cproquest_cross%3E1027834249%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1027834249&rft_id=info:pmid/22739137&rfr_iscdi=true |